SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 7 — Focused Visit (Care-plan review) — Judy Garland — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJudy Garland
Date of birth1922-06-10
IdentifiersMRN HR-ML005-SYN-TD; SSN (made up) 000-05-6127
Document date1955-10-26
AuthorMargaret Ellsworth-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Four-month review: phenobarbital taper, sleep, mood and laboratory checks. [S]

History of Present Illness

Ms. Garland returns four weeks after her preventive visit. She lowered phenobarbital to 40.5 mg a day at that visit and to 32.4 mg a day two weeks ago. After the last step she lay awake for three nights and felt shaky inside, without a tremor others could see; it has eased but not fully gone, and she would like to stay at this dose for a while. She has taken no secobarbital, stimulant or other sedative. She sleeps about six hours on most nights. Her mood is good and she is enjoying work again. She eats three meals on most days and says she feels stronger. Her HIV, hepatitis C and hepatitis B tests from the preventive visit were nonreactive, and she was told by phone. She wants to talk about stopping smoking once the taper is over. [S]

ElementDetail
Phenobarbital32.4 mg a day for two weeks; three nights of rebound wakefulness after the step
Other sedatives or stimulantsNone
SleepAbout six hours; Insomnia Severity Index 10
MoodPHQ-9 5; GAD-7 5
Screening resultsHIV, hepatitis C and hepatitis B nonreactive

Review of Systems

SystemResultFinding
ConstitutionalNegativeEnergy good; weight up gradually
NeurologicalNegativeNo visible tremor or seizure-like episodes; brief inner shakiness after the last step, easing
PsychiatricNegativeMood good; PHQ-9 5; no thoughts of suicide or self-harm

3 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicineTwo capsules at bedtime; no extra dosesOral route1955-06-22 to 1955-07-06completedS
Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energyOne tablet each morningOral route1955-06-22 to 1955-07-20completedS
Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stopOne tablet each morning for two weeks, then stopOral route1955-07-20 to 1955-08-03completedS
Sertraline 25 mg oral tablet, one tablet dailyOne tablet dailyOral route1955-06-22 to 1955-06-29completedS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route1955-06-29activeS
Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbitalOne tablet three times dailyOral route1955-07-06 to 1955-07-20completedS
Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a timePer the written taper schedule, in two or three divided dosesOral route1955-07-20activeS
Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks150 mg intramuscularly every 13 weeksIntramuscular route1955-06-22activeS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for throat pain, no more than 3,000 mg a day, for up to five daysTwo tablets every 6 hours as needed, up to 3,000 mg a dayOral route1955-08-17 to 1955-08-22completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1955-10-26Body height151cmS
1955-10-26Body weight50kgS
1955-10-26Body mass index (BMI) [Ratio]21.9kg/m2S
1955-10-26Systolic blood pressure112mm[Hg]S
1955-10-26Diastolic blood pressure70mm[Hg]S
1955-10-26Heart rate68/minS
1955-10-26Respiratory rate14/minS
1955-10-26Body temperature36.6CelS
1955-10-26Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1955-10-26Hemoglobin [Mass/volume] in Blood12.9g/dL12-15.5 g/dLNormalS
1955-10-26MCV [Entitic mean volume] in Red Blood Cells by Automated count87fL80-100 fLNormalS
1955-10-26Platelets [#/volume] in Blood by Automated count26810*3/uL150-400 10*3/uLNormalS
1955-10-26Ferritin [Mass/volume] in Serum or Plasma41ng/mL15-150 ng/mLNormalS
1955-10-26Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1955-10-26Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1955-10-26Creatinine [Mass/volume] in Serum or Plasma0.68mg/dL0.59-1.04 mg/dLNormalS
1955-10-26Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1950)/1.73 sq M118mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1955-10-26Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma23U/L10-35 U/LNormalS
1955-10-26Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L7-35 U/LNormalS
1955-10-26Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma48U/L5-40 U/LHighS
1955-10-26Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1955-10-26Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]5{score}S

Physical Exam

Vital signs recorded on 1955-10-26; see the Vital Signs section. [S]

SystemFinding
GeneralWell; blood pressure 112/70, pulse 68; weight 50.0 kg, BMI 21.9
NeurologicalNo tremor with arms outstretched; no nystagmus
PsychiatricBright and engaged; no signs of sedation or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pillsactiveconfirmed F13.20S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis.
Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pillsactiveconfirmed F15.10S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription.
Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescenceactiveconfirmed G47.00S — Synthetic modern diagnosis anchored to the documented sleeping pills.
Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implantsactiveconfirmed Z30.013S — Synthetic contraception need; the birth is documented.
Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomaniaactiveconfirmed F32.1S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used.
Acute laryngitis, probably viral, during rehearsals, treated with voice rest and supportive care; resolvedresolvedconfirmed J04.0S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
Medication safetyBarbiturate dose, adherence, extra doses, and withdrawal signs (tremor, sweating, pulse, sleep, seizure warning signs)Every visitCompleted today32.4 mg a day; mild rebound wakefulness after the last step; no tremor or other withdrawal signs
Medication safetyTaper paceReductions of no more than about 20% every two weeks, slower toward the end; pause for symptoms, illness or a major performanceCompleted today56.7 to 48.6 to 40.5 to 32.4 mg a day at two-week intervals; paused today for four weeks; later steps of 8.1 mg
Medication safetyPrescription drug monitoring program checkBefore every controlled-substance prescriptionCompleted todayOnly this clinic's prescriptions
LaboratoryUrine drug testing, explained as part of careAt the start, after the change to phenobarbital, and periodically during the taperCompleted todayBarbiturates only; amphetamine negative
Medication safetyLimited dispensing, locked storage and take-back of unused capsulesSeven days at first, then two weeks at a timeCompleted todayTwo-week supplies; locked box
Medication safetyMood, sleep, energy and appetite after stopping the stimulantEach visitCompleted todayNo stimulant for twelve weeks; urges rare
LaboratoryBlood count and liver tests on phenobarbitalBaseline, then at three to four monthsCompleted todayHemoglobin 12.9 g/dL, MCV 87 fL, platelets 268; ferritin 41 ng/mL; sodium 140, potassium 4.2, creatinine 0.68 mg/dL, eGFR 118; AST 23, ALT 20 U/L; GGT 48 U/L, mildly raised by enzyme induction
SurveyCBT for insomnia, sleep diary and Insomnia Severity IndexWeekly CBT-I sessions; sleep diary and index at each visitCompleted todayInsomnia Severity Index 10
Medication safetyNew hypnotic (benzodiazepine, Z-drug, trazodone or antihistamine)Not recommended as a replacementNot indicatedNo new hypnotic
SurveyDepression (PHQ-9)At least monthly during acute treatmentCompleted todayPHQ-9 5, item 9 scored 0; monthly since the corrective action
SurveyAnxiety (GAD-7)With each PHQ-9 while anxiety is treatedCompleted todayGAD-7 5
Medication safetySertraline adherence and side effectsTwo weeks after starting or changing the dose, then each visitCompleted today50 mg daily; no side effects
SurveySuicide-risk review (C-SSRS screen since the last visit), safety plan, means safety and the 988 Suicide & Crisis LifelineEvery visitCompleted todayC-SSRS screen negative since the last visit; the 988 Suicide & Crisis Lifeline in her phone
ExaminationWeight, meals and disordered-eating screen, without a weight targetEvery visitCompleted todayWeight 50.0 kg, BMI 21.9; three meals on most days; she feels stronger
Medication safetyContraception that phenobarbital does not weakenMedroxyprogesterone every 13 weeksUp to dateSecond injection at the preventive visit; next due in nine weeks
Medication safetyNaloxoneReassess at every visit and whenever an opioid is prescribedNot indicatedNo opioids prescribed or used
Self-managementAlcohol and other sedativesEvery visitCompleted todayNo alcohol; no other sedatives

Goal progress:

Guideline basis: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); The ASAM Clinical Practice Guideline on Alcohol Withdrawal Management (2020); The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder (2024); Management of Chronic Insomnia Disorder in Adults: A Clinical Practice Guideline From the American College of Physicians (2016); U.S. Medical Eligibility Criteria for Contraceptive Use, 2024 (2024); Prescription Drug Monitoring Programs (PDMPs) (2026); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026)

Follow-up: Nurse phone check before each remaining step. Visit in four weeks to restart the taper. Addiction medicine review when the taper ends. Smoking cessation plan at the end of the taper. [S]